The latest biotech news

News and Trends 18 Mar 2019

Shares Drop 40% as Allergy Therapeutics Announces Failed Phase III Trial

Allergy Therapeutics has revealed that its immunotherapy for birch pollen allergy did not result in a significant symptom improvement when compared to a placebo. As a direct result of the announcement, the shares of Allergy Therapeutics on the London Stock Exchange dropped over 40% within two hours. The phase III trial enrolled 582 people across […]

March 18, 2019 - 2 minutesmins - By Clara Rodríguez Fernández

microsoft synthace oxford biomedica gene therapy cell therapy

News and Trends 14 Mar 2019

Microsoft Aims to Make Cell Therapies Cheaper with Artificial Intelligence

Microsoft has launched a collaboration with the UK company Oxford BioMedica to use Microsoft’s artificial intelligence technology to make gene and cell therapy manufacturing easier and cheaper. Genetically programming cells and viruses to make cell and gene therapies is not as simple as programming a computer. Organisms have many layers of complexity and unpredictability, sometimes […]

March 14, 2019 - 2 minutesmins - By Jonathan Smith

arthritis pediatric juvenile idiopathic Leuven

News and Trends 13 Mar 2019

Artificial Intelligence Detects Juvenile Arthritis in the Blood

Using artificial intelligence, a Belgian research group can diagnose juvenile arthritis from blood samples with almost 90% accuracy and identify different forms of the disease, something that is not currently possible. Juvenile idiopathic arthritis causes joint pain, swelling and stiffness in children under the age of 16. The disease is hard to treat because there […]

March 13, 2019 - 3 minutesmins - By Jonathan Smith

osteoarthritis stem cell regenerative medicine

News and Trends 12 Mar 2019

Stem Cells and Hydrogel Make Potential Osteoarthritis Treatment

Scientists from the Netherlands have received a €600,000 grant to test a treatment for osteoarthritis in humans that combines hydrogels and stem cells to help the knee joint heal. In osteoarthritis, the cartilage in joints such as the knees breaks down, causing stiffness and pain. There is no cure at the moment, and most current […]

March 12, 2019 - 3 minutesmins - By Jonathan Smith

geneuro multiple sclerosis neuron viral dna

News and Trends 12 Mar 2019

Blocking Hidden Viral Protein Shows Promise for Treating Multiple Sclerosis

An antibody that blocks the action of a hidden viral protein encoded by our genome shows encouraging signs of slowing down the progression of multiple sclerosis, according to the Swiss biotech GeNeuro which carried out the research. GeNeuro’s monoclonal antibody drug targets the hidden viral protein because it’s linked to the occurrence of multiple sclerosis, […]

March 12, 2019 - 3 minutesmins - By Jonathan Smith

News and Trends 11 Mar 2019

Danish Biotech to Develop CRISPR-Based Microbiome Treatments

SNIPR Biome has raised €43M in Series A funds to develop treatments that precisely target ‘bad’ bacteria using CRISPR gene editing, while keeping the rest of the patient’s microbiome intact. Founded with €2.6M seed investment from the Lundbeck Foundation in 2017, SNIPR Biome was the first exploratory investment for the Danish organisation’s Emerge fund, which […]

March 11, 2019 - 2 minutesmins - By Helen Albert

News and Trends 11 Mar 2019

Monthly Injection Proves as Good as Daily Pills Against HIV in Phase III

Two phase III trials conducted by ViiV Healthcare have concluded that a monthly injection of two anti-HIV drugs is as effective as the standard daily treatment taken by people infected with HIV. The results showed that, after 11 months, the monthly treatment achieved virus suppression levels of over 90% and similar to those of conventional […]

March 11, 2019 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 8 Mar 2019

HIV Drug Shows Promise for Treating Ulcerative Colitis Patients

A small molecule drug, developed by the company Abivax for treating HIV, has also shown promise for patients with the inflammatory bowel disease ulcerative colitis, reducing the disease severity consistently for over six months. Abivax tested the drug on patients with moderate-to-severe cases of ulcerative colitis, an inflammatory bowel condition that causes rectal bleeding and […]

March 8, 2019 - 3 minutesmins - By Jonathan Smith

influenza virus antiviral drugs atriva therapeutics germany tuebingen 1

News and Trends 8 Mar 2019

Flu Resistant to Antivirals? This Biotech Has a Drug for That

We are visiting the medieval German city of Tübingen this week. It hosts the biotech Atriva Therapeutics, which is developing antiviral drugs for influenza that can circumvent drug resistance. Mission: To make antiviral drugs that, unlike conventional drugs, target the host cell instead of the virus. This can prevent the virus from building resistance to […]

March 8, 2019 - 3 minutesmins - By Jonathan Smith

News and Trends 6 Mar 2019

Second Patient Achieves HIV Remission After Bone Marrow Transplant to Treat Cancer

For the second time in history, an HIV-positive patient with blood cancer has achieved HIV remission following a customized bone marrow transplant to treat their cancer from an HIV-resistant donor. The HIV-positive patient received a bone marrow transplant to treat the blood cancer Hodgkin’s lymphoma, from which he also suffered. The researchers used this cancer […]

March 6, 2019 - 3 minutesmins - By Jonathan Smith

News and Trends 5 Mar 2019

Seventure Continues Microbiome Investment Success with Second Fund

After the success of the world’s first fund dedicated to companies in nutrition, digital health, and the microbiome, the French venture capital firm Seventure Partners has completed the first closing of a second microbiome fund, which is expected to total €200M. The fund is the successor to Seventure’s Health for Life Capital fund, which was […]

March 5, 2019 - 3 minutesmins - By Jonathan Smith

biogen nightstar therapeutics gene therapy ophthalmology

News and Trends 4 Mar 2019

Biogen Acquires UK Biotech Developing Gene Therapy for Blindness

The big US biotech Biogen has agreed to acquire Nightstar Therapeutics for €773M ($877M), including Nightstar’s candidate gene therapies for inherited blindness. Expected to be complete by mid-2019, Biogen’s acquisition of Nightstar bags it the UK company’s most advanced program. Currently in phase III, the therapy targets choroidemia, an incurable genetic condition which causes progressive […]

March 4, 2019 - 2 minutesmins - By Jonathan Smith

Knowledge hub

Categories

Webinar: Organoids in cancer research - Paving the way for faster drug development across cancer indications

10 biotech companies leading the way in Denmark

Approaches

Therapeutic areas

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Webinar: Organoids in cancer research - Paving the way for faster drug development across cancer indications

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Shares Drop 40% as Allergy Therapeutics Announces Failed Phase III Trial

Microsoft Aims to Make Cell Therapies Cheaper with Artificial Intelligence

Artificial Intelligence Detects Juvenile Arthritis in the Blood

Stem Cells and Hydrogel Make Potential Osteoarthritis Treatment

Blocking Hidden Viral Protein Shows Promise for Treating Multiple Sclerosis

Danish Biotech to Develop CRISPR-Based Microbiome Treatments

Monthly Injection Proves as Good as Daily Pills Against HIV in Phase III

HIV Drug Shows Promise for Treating Ulcerative Colitis Patients

Flu Resistant to Antivirals? This Biotech Has a Drug for That

Second Patient Achieves HIV Remission After Bone Marrow Transplant to Treat Cancer

Seventure Continues Microbiome Investment Success with Second Fund

Biogen Acquires UK Biotech Developing Gene Therapy for Blindness

Subscribe to our newsletter to get the latest biotech news!

Webinar: Organoids in cancer research - Paving the way for faster drug development across cancer indications

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Webinar: Organoids in cancer research - Paving the way for faster drug development across cancer indications

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!